BN Business News
Ajouter votre entreprise →
Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.

Réglementation et droit · 08/09/20161 min de lecture

Announcement of Requirements and Registration for “Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test” Challenge

Traduction automatique locale · Langue originale de la source

Résumé

Through the "Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test" Challenge (the "Challenge"), the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR) are searching for novel and innovative in vitro diagnostic tests that would rapidly inform clinical treatment decisions and be of potential significant clinical and public health utility to combat the development and spread of antibiotic resistant bacteria. Tests of interest will provide novel, innovative solutions for use in inpatient and/or outpatient settings. The goal of the challenge is to identify a diagnostic test that when utilized would lead to more rapid clinical decision making such that antibiotic use and/or outcomes of patients infected with resistant pathogens are fundamentally improved compared to current standard of care, and/or reduce transmission of resistant pathogens such that population infection rates significantly decrease. The Challenge competition seeks to incentivize a broad range of scientists, engineers, and innovators to develop diagnostic tests that would enable h

Langue originale de la source: Federal Register — All DocumentsOuvrir le communiqué original →

Explorer les analyses

Analyses business →